Milestone Pharmaceuticals Inc (MIST)

Etorro trading 970x250
Milestone Pharmaceuticals Inc (MIST) Logo

About Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada. Address: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6

Milestone Pharmaceuticals Inc News and around…

Latest news about Milestone Pharmaceuticals Inc (MIST) common stock and company :

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 May, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted three new employees incentive stock options to purchase an aggregate of 92,000 common shares, at a per share exercise price of $5.48, the closing price of Milestone's common stock on May 16, 2022. The awards were made pursuant to the NASDAQ inducement grant exception as a

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
23 May, 2022 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
17 May, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.

Milestone Pharmaceuticals Becomes Oversold (MIST)
12 May, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Milestone Pharmaceuticals: Q1 Earnings Insights
12 May, 2022 FinancialContent

Milestone Pharmaceuticals (NASDAQ:MIST) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's ...

Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
12 May, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2022, and provided a clinical and corporate update.

Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
30 Apr, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced data from NODE-302, its Phase 3 open-label extension study of etripamil nasal spray, the Company's novel, investigational, calcium channel blocker in patients with paroxysmal supraventricular tachycardia (PSVT). The presentation, titled "Etripamil Nasal Spray Is Effective and Safe for Conversion of Repeated Spontaneous

Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022
22 Apr, 2022 FinancialContent

Upgrades For United Airlines Holdings Inc (NASDAQ:UAL), Argus Research upgraded the previous rating of Hold to Buy. For the first ...

Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have made a respectable return of 36% over the past year
15 Apr, 2022 Yahoo! Finance

While Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) shareholders are probably generally happy, the stock hasn't had...

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
14 Apr, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Thursday, April 21, 2022 at 1:00 p.m. ET. The event will focus on etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT). Etripamil is currently being assessed in mult

Milestone Pharmaceuticals: Q4 Earnings Insights
24 Mar, 2022 FinancialContent

Milestone Pharmaceuticals (NASDAQ:MIST) reported its Q4 earnings results on Thursday, March 24, 2022 at 07:20 ...

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update
24 Mar, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a clinical and corporate update.

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
01 Mar, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of management will present at the following investor conferences:

Stocks That Hit 52-Week Lows On Friday
25 Feb, 2022 FinancialContent

During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week ...

Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer
16 Feb, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha is a cardiac electrophysiologist who brings to Milestone over thirty years of global drug development and clinical experience across a range of therapeutic areas, with a focus on cardiovascular medicine.

Could The Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Ownership Structure Tell Us Something Useful?
14 Feb, 2022 Yahoo! Finance

The big shareholder groups in Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) have power over the company. Institutions...

Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
04 Jan, 2022 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference being held on January 10-13, 2022.

Milestone Pharmaceuticals (NASDAQ:MIST) Is In A Good Position To Deliver On Growth Plans
14 Dec, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

70 Biggest Movers From Yesterday
16 Nov, 2021 FinancialContent

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be ...

Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
15 Nov, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new data from a post-hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the Company's novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). The analysis demonstrated that etripamil sig

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov, 2021 FinancialContent

Biotech stocks declined for the second straight week amid a broader market pullback, along withearnings news from small- and ...

Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
12 Nov, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update.

Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 18% over the last year
15 Oct, 2021 Yahoo! Finance

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...

Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
22 Sep, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Amit Hasija, Chief Financial Officer and Executive Vice President of Corporate Development, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 10:00 a.m. ET. The conference will be held in a virtual meeting format.

Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.

What Kind Of Shareholders Own Milestone Pharmaceuticals Inc. (NASDAQ:MIST)?
16 Aug, 2021 Yahoo! Finance

If you want to know who really controls Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ), then you'll have to look at the...

Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
11 Aug, 2021 Yahoo! Finance

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update.

12 Health Care Stocks Moving In Tuesday's After-Market Session
06 Jul, 2021 FinancialContent

Gainers Opiant Pharmaceuticals (NASDAQ:OPNT) stock increased by 35.04% to $17.9 during Tuesday's after-market session. Opiant ...

Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
22 May, 2021 FinancialContent

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.

Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China
17 May, 2021 FinancialContent

Milestone Pharmaceuticals Inc(NASDAQ: MIST)hit a major snag last Marchwhen its investigational etripamil nasal ...

Milestone Pharmaceuticals Inc (MIST) is a NASDAQ Common Stock listed in , ,

970x250